We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Humacyte, Inc. (NASDAQ:HUMA) is ...

Humacyte was riding high in December 2024 when it secured an FDA green light for a groundbreaking implant. Now, as it looks ...

Humacyte, Inc. (HUMA) closed at $0.70 in the latest trading session, marking a -1.14% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.8%. Meanwhile, the Dow ...

Next Generation contract makes Symvess more easily accessible to 170 VA hospitals –- SAC awards require intensive product ...

Humacyte, Inc. (HUMA) ended the recent trading session at $0.84, demonstrating a +2.66% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 1.02% ...

Humacyte is cutting about a quarter of its workforce as it revamps its commercial strategy. Durham biotech's breakthrough ...

Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech ...

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed ...

DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

In the latest trading session, Humacyte, Inc. (HUMA) closed at $5.17, marking a -1.34% move from the previous day. This change lagged the S&P 500's daily loss of 0.16%. Elsewhere, the Dow saw an ...

Humacyte (NASDAQ:HUMA) reported first-quarter 2026 Symvess sales of $0.5 million and outlined a series of commercial, ...